vs

Side-by-side financial comparison of Jaguar Health, Inc. (JAGX) and Rithm Property Trust Inc. (RPT). Click either name above to swap in a different company.

Rithm Property Trust Inc. is the larger business by last-quarter revenue ($3.4M vs $3.2M, roughly 1.1× Jaguar Health, Inc.). Rithm Property Trust Inc. runs the higher net margin — 95.4% vs -717.2%, a 812.6% gap on every dollar of revenue. On growth, Jaguar Health, Inc. posted the faster year-over-year revenue change (-7.8% vs -39.7%). Over the past eight quarters, Jaguar Health, Inc.'s revenue compounded faster (17.3% CAGR vs -43.2%).

Jaguar Health, Inc. is a commercial-stage biopharmaceutical firm developing and selling plant-derived prescription medicines for humans and animals. Its products target unmet gastrointestinal treatment needs, with main markets in North America and select European regions, covering human health and animal health segments.

Rithm Capital Corp. (Rithm) is an American investment management company headquartered in New York that focuses on real estate and alternative investments.

JAGX vs RPT — Head-to-Head

Bigger by revenue
RPT
RPT
1.1× larger
RPT
$3.4M
$3.2M
JAGX
Growing faster (revenue YoY)
JAGX
JAGX
+31.9% gap
JAGX
-7.8%
-39.7%
RPT
Higher net margin
RPT
RPT
812.6% more per $
RPT
95.4%
-717.2%
JAGX
Faster 2-yr revenue CAGR
JAGX
JAGX
Annualised
JAGX
17.3%
-43.2%
RPT

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
JAGX
JAGX
RPT
RPT
Revenue
$3.2M
$3.4M
Net Profit
$-23.2M
$3.2M
Gross Margin
32.0%
Operating Margin
-656.6%
99.6%
Net Margin
-717.2%
95.4%
Revenue YoY
-7.8%
-39.7%
Net Profit YoY
-133.9%
11.2%
EPS (diluted)
$10.27
$-0.26

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
JAGX
JAGX
RPT
RPT
Q4 25
$3.2M
$3.4M
Q3 25
$3.1M
$4.0M
Q2 25
$3.0M
$4.2M
Q1 25
$2.2M
$249.0K
Q4 24
$3.5M
Q3 24
$3.1M
Q2 24
$2.7M
Q1 24
$2.4M
Net Profit
JAGX
JAGX
RPT
RPT
Q4 25
$-23.2M
$3.2M
Q3 25
$-9.5M
$-273.0K
Q2 25
$-10.4M
$1.9M
Q1 25
$-10.5M
$-3.4M
Q4 24
$-9.9M
Q3 24
$-9.9M
Q2 24
$-9.5M
Q1 24
$-9.2M
Gross Margin
JAGX
JAGX
RPT
RPT
Q4 25
32.0%
Q3 25
82.7%
Q2 25
82.3%
Q1 25
76.7%
Q4 24
84.1%
Q3 24
82.6%
Q2 24
84.3%
Q1 24
81.7%
Operating Margin
JAGX
JAGX
RPT
RPT
Q4 25
-656.6%
99.6%
Q3 25
-234.8%
-6.2%
Q2 25
-268.8%
45.7%
Q1 25
-425.5%
-1416.5%
Q4 24
-232.5%
Q3 24
-233.7%
Q2 24
-264.5%
Q1 24
-349.4%
Net Margin
JAGX
JAGX
RPT
RPT
Q4 25
-717.2%
95.4%
Q3 25
-308.2%
-6.8%
Q2 25
-349.3%
45.1%
Q1 25
-472.6%
-1363.1%
Q4 24
-282.7%
Q3 24
-317.1%
Q2 24
-348.8%
Q1 24
-392.4%
EPS (diluted)
JAGX
JAGX
RPT
RPT
Q4 25
$10.27
$-0.26
Q3 25
$-6.28
$-0.03
Q2 25
$-10.26
$0.01
Q1 25
$-16.70
$-0.08
Q4 24
$-14.62
Q3 24
$-1.05
Q2 24
$-4.04
Q1 24
$-0.06

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
JAGX
JAGX
RPT
RPT
Cash + ST InvestmentsLiquidity on hand
$968.0K
$79.3M
Total DebtLower is stronger
Stockholders' EquityBook value
$-18.7M
$291.6M
Total Assets
$38.3M
$1.0B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
JAGX
JAGX
RPT
RPT
Q4 25
$968.0K
$79.3M
Q3 25
$3.5M
$81.4M
Q2 25
$2.2M
$98.6M
Q1 25
$5.7M
$97.4M
Q4 24
$8.0M
Q3 24
$13.3M
Q2 24
$16.0M
Q1 24
$11.7M
Stockholders' Equity
JAGX
JAGX
RPT
RPT
Q4 25
$-18.7M
$291.6M
Q3 25
$4.4M
$291.7M
Q2 25
$6.9M
$294.7M
Q1 25
$830.0K
$296.1M
Q4 24
$6.5M
Q3 24
$13.1M
Q2 24
$16.6M
Q1 24
$11.8M
Total Assets
JAGX
JAGX
RPT
RPT
Q4 25
$38.3M
$1.0B
Q3 25
$49.5M
$1.0B
Q2 25
$48.3M
$1.0B
Q1 25
$51.5M
$1.0B
Q4 24
$53.4M
Q3 24
$58.5M
Q2 24
$61.5M
Q1 24
$55.4M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
JAGX
JAGX
RPT
RPT
Operating Cash FlowLast quarter
$-5.5M
$-8.3M
Free Cash FlowOCF − Capex
FCF MarginFCF / Revenue
Capex IntensityCapex / Revenue
Cash ConversionOCF / Net Profit
-2.56×
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
JAGX
JAGX
RPT
RPT
Q4 25
$-5.5M
$-8.3M
Q3 25
$-5.8M
Q2 25
$-25.0K
Q1 25
$-7.3M
$-1.6M
Q4 24
$-7.8M
Q3 24
Q2 24
Q1 24
$-7.0M
Cash Conversion
JAGX
JAGX
RPT
RPT
Q4 25
-2.56×
Q3 25
Q2 25
-0.01×
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

JAGX
JAGX

Human Health Segment$3.2M97%
Other$83.0K3%

RPT
RPT

Segment breakdown not available.

Related Comparisons